Clinical Trials · NCT03707990
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 88
- Start date
- Oct 2018
- Locations
- 1 site, United States
- Primary endpoint
- Number of treatment emergent adverse events (TEAEs)